Main Article Content
Abstract
Introduction: Precise quantification of hepatic steatosis is central to managing metabolic dysfunction-associated steatotic liver disease (MASLD). MRI proton density fat fraction (MRI-PDFF) has displaced biopsy as a reproducible biomarker, yet real-world comparative monitoring data and formal early-response prediction remain scarce in Indonesian practice. We quantified steatosis reversibility on serial MRI-PDFF during SGLT2-inhibitor versus GLP-1 receptor agonist therapy and tested whether an early scan predicts response.
Methods: In this prospective cohort at a tertiary hospital in Palembang, Indonesia, 90 adults with MASLD (baseline PDFF ≥5.5%) were grouped by prescribed therapy (SGLT2i, n=45; GLP-1 RA, n=45) and imaged at baseline, Month 3 and Month 6 on a 3.0 T scanner using a confounder-corrected 3D multi-echo spoiled gradient-echo sequence. Two blinded radiologists measured PDFF across Couinaud segments V/VI/VIII; response was a ≥30% relative reduction. Analyses (STARD 2015) included linear mixed-effects modelling, κ and intraclass correlation, ROC (DeLong), likelihood ratios and multivariable logistic regression.
Results: PDFF fell in both arms (both p<0.001; partial η²=0.66 and 0.79). Responder rate was 75.6% (95% CI 61.3–85.8) with GLP-1 RA versus 40.0% (27.0–54.5) with SGLT2i (OR 4.64; p=0.001). A Month-3 decline ≥16.9% predicted Month-6 response with AUC 0.895 (0.823–0.967), sensitivity 96.2%, specificity 78.9%, LR+ 4.57, LR− 0.05. Inter-reader agreement was near-perfect (ICC 0.986; κ 0.861). GLP-1 RA therapy and higher baseline PDFF independently predicted response.
Conclusion: Serial MRI-PDFF reliably quantified pharmacologically-induced steatosis reversibility, with GLP-1 RA producing greater fat loss and an early scan accurately triaging responders. MRI-PDFF is a robust, decision-useful monitoring biomarker deployable in tertiary settings.
Keywords
Article Details
Sriwijaya Journal of Radiology and Imaging Research (SJRIR) allow the author(s) to hold the copyright without restrictions and allow the author(s) to retain publishing rights without restrictions, also the owner of the commercial rights to the article is the author.
